Adding a GABAergic agent could smooth that shift or could create unpredictable swings in alertness if dosing is poorly timed
While tirzepatide has not been shown to directly cause gastrointestinal ulceration in clinical trials, its effects on motility and bowel habits may create conditions where bleeding from benign sources becomes more likely
Tirzepatide's greater glucose-lowering effect compared to semaglutide means hypoglycemia risk may increase, especially if you are also taking sulfonylureas or insulin
This was noted with peripheral nerve injury (Gjurasin et al., 2010) and central nervous disturbances (i.e., traumatic brain injury (Tudor et al., 2010), various encephalopathies (Ilic et al., 2009
You must never, ever try to guess or calculate your own dose
Once opened, use promptly under sterile laboratory conditions